Regorafenib-resistant PDGFR mutants don't bind regorafenib

Stable Identifier
R-HSA-9674408
Type
Reaction [transition]
Species
Homo sapiens
Compartment
plasma membrane, cytosol
ReviewStatus
5/5
Locations in the PathwayBrowser
Expand all
General
SVG | 
PNG
Low
Medium
High
 | PPTX  | SBGN
Regorafenib-resistant PDGFR mutants don't bind regorafenib
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
Regorafenib only weakly inhibits the activity of the most prevalent PDGFRA mutation, D842V (Evans et al, 2017).
Literature References
PubMed ID Title Journal Year
29093181 A precision therapy against cancers driven by KIT/PDGFRA mutations

Heinrich, MC, Zhang, Y, Hodous, BL, Shutes, A, Lengauer, C, Evans, EK, Kohl, N, Wolf, B, Schöffski, P, Zhu, XJ, Kim, JL, Gebreyohannes, YK, Gardino, AK, Wozniak, A, DiPietro, L, Lydon, N, Wilson, K, Brooijmans, N, Schmidt-Kittler, O, Boral, A, Miller, S, LaBranche, TP, Deangelo, DJ, Davis, A, Guzi, T, Wilson, D

Sci Transl Med 2017
Participants
Input
Participates
as an event of
Normal reaction
PDGFRs bind type II TKI (Homo sapiens)
Functional status

Loss of function of PDGFRA D842V [plasma membrane]

Normal Entity
Disease Entity
Status
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Authored
Rothfels, K  (2020-02-25)
Reviewed
Ip, CKM  (2020-02-06)
Created
Rothfels, K  (2020-01-13)
Cite Us!